PPD, Inc. today announced it has completed the acquisition of InnoPharm, an independent contract research organization based in Smolensk, Russia, strengthening its ability to offer Phase II-IV clinical trials support, data management and biostatistics services in Eastern Europe.
In addition to Smolensk, PPD has added offices in Moscow and St. Petersburg, Russia, and Kiev, Ukraine, with this acquisition. As one of the first CROs in Russia, InnoPharm was a pioneer in the implementation of good clinical practice (GCP) in Russia and Ukraine and delivers a broad range of clinical and data management services to pharmaceutical and biotechnology companies.
“The number of clinical trials approved in Russia has nearly doubled over the past six years as the country continues to emerge as a high-growth market for clinical research,” said Fred Eshelman, chief executive officer of PPD. “Acquiring InnoPharm strengthens our presence in Russia and Ukraine and will serve as the foundation for continued growth in a region we have targeted for expansion.”
InnoPharm has worked as a subcontractor for PPD since 2004. Sergey Sudilovsky, M.D., Ph.D., currently director general of InnoPharm, will oversee operations in Russia and Ukraine for PPD. Dr. Sudilovsky has more than 15 years of experience with InnoPharm, having spent the past 10 years as director general.
PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 33 countries and more than 10,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients.
Contact:
PPD, Inc.
Media:
Sue Ann Pentecost, 919-456-5890
sueann.pentecost@rtp.ppdi.com
or
Analysts/Investors:
Luke Heagle, 910-558-7585
luke.heagle@wilm.ppdi.com
Source: PPD, Inc.
In addition to Smolensk, PPD has added offices in Moscow and St. Petersburg, Russia, and Kiev, Ukraine, with this acquisition. As one of the first CROs in Russia, InnoPharm was a pioneer in the implementation of good clinical practice (GCP) in Russia and Ukraine and delivers a broad range of clinical and data management services to pharmaceutical and biotechnology companies.
“The number of clinical trials approved in Russia has nearly doubled over the past six years as the country continues to emerge as a high-growth market for clinical research,” said Fred Eshelman, chief executive officer of PPD. “Acquiring InnoPharm strengthens our presence in Russia and Ukraine and will serve as the foundation for continued growth in a region we have targeted for expansion.”
InnoPharm has worked as a subcontractor for PPD since 2004. Sergey Sudilovsky, M.D., Ph.D., currently director general of InnoPharm, will oversee operations in Russia and Ukraine for PPD. Dr. Sudilovsky has more than 15 years of experience with InnoPharm, having spent the past 10 years as director general.
PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 33 countries and more than 10,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients.
Contact:
PPD, Inc.
Media:
Sue Ann Pentecost, 919-456-5890
sueann.pentecost@rtp.ppdi.com
or
Analysts/Investors:
Luke Heagle, 910-558-7585
luke.heagle@wilm.ppdi.com
Source: PPD, Inc.
0 comments:
Post a Comment